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Abstract
Background: Monitoring osteoporosis therapy by measurement of bone turnover markers (BTMs) might detect
non-compliance in an earlier stage of anti-osteoporosis treatment and improve persistence.
Methods: BTMs were measured in two groups. The first group consisted of patients newly diagnosed with
osteoporosis and starting treatment. We observed which proportion of patients had a decrease of serum levels of
procollagen type 1 N-terminal propeptide (P1NP) and C-terminal crosslinking telopeptide (CTX) greater than the
least significant change (LSC) after 3 months of treatment. Secondly, we determined which proportion of patients
who were treated with bisphosphonates for ≥ 3 months reached the biological goal of therapy, BTMs in the lower
half of the normal premenopausal range. P1NP and CTX were also measured in a reference population of 34
healthy premenopausal women.
Results: In the first group 31 patients were included, in 25 patients (81%) levels of both markers decreased with
≥ LSC, in the other patients a possible explanation was found.
In the second group 95 patients were included, in 95% the serum P1NP levels and CTX levels were in the lower
half of the premenopausal range. In 6 of the 7 patients with a level above the premenopausal range a possible
explanation was found.
Conclusion: A decrease in bone turnover ≥ LSC can be observed in the majority of newly treated patients. In
chronically treated patients, 95% have a bone turnover in the premenopausal range. In most patients with
inadequate suppression of BTMs during bisphosphonate treatment, an explanation was found. Monitoring
treatment effect with BTMs in daily practice is feasible, and might be an additive tool in improving therapy
compliance.
Background
Osteoporosis is a major public health problem that pri-
marily affects elderly women. Reduced bone mineral den-
sity increases fracture risk and results in considerable
morbidity, mortality, and health care costs [1]. In clinical
studies treatment with oral bisphosphonates has been
shown effective, reducing vertebral fracture risk with
40-50% [2,3]. An important problem in daily clinical
practice however, is the poor long-term compliance and
persistence, diminishing the intended effect on BMD and
fracture risk [4,5].
Although repeated dual × ray absorptiometry (DXA)
measurements are sometimes used to monitor therapy,
changes in bone mineral density (BMD) are small over
the years and reliable repeated BMD measurements are
only possible after 1-2 years [6,7].
The least significant change (LSC, the difference that
represents a statistically significant change) of BTMs can
already be detected after 3-6 months of treatment [8]
with anti-resorptives and enables earlier monitoring of
therapy. The size of the LSC varies between different
types of bone markers and depends on the intra-indivi-
dual variation and coefficient of variation of the assay [9].
The goal of treatment has been determined as a reduc-
tion of serum BTM levels within the premenopausal
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range or to decrease serum BTM levels with a percentage
greater than the LSC [10].
It has been suggested that reinforcing patients by
informing them about the change in their BTMs during
treatment might have beneficial effects on persistence to
therapy and even on reducing the risk of vertebral frac-
tures. In the Improving Measurements of Persistence on
Actonel Treatment (IMPACT) study osteoporotic patients
treated with risedronate were divided into two groups, one
group receiving reinforcement based on changes in BTMs
(a decrease of > 30%, no change, an increase > 30%) and
one group receiving no reinforcement. Patients with posi-
tive reinforcement (> 30% decrease in BTM) showed a sig-
nificant improvement in persistence and had a lower
incidence of new radiologically reported vertebral frac-
tures. Patients receiving negative reinforcement however
(> 30% increase in BTM), showed a significant decline in
persistence compared to the group receiving no reinforce-
ment [11].
The aim of this study is to observe in daily clinical prac-
tice in which proportion of patients starting with bispho-
sphonate treatment the serum levels of procollagen type 1
N-terminal propeptide (P1NP, marker of bone formation)
and C-terminal crosslinking telopeptide (CTX, marker of
bone resorption) show a decrease ≥ LSC, three months
after starting with therapy. Additionally, we observed in
which proportion of patients, diagnosed with osteoporosis
and treated for at least three months with bisphospho-
nates, the serum level of P1NP and CTX is in the lower
half of the premenopausal range.
Methods
To observe short- and long-term effects we included two
different types of patients visiting the osteoporosis outpati-
ent clinic at the VU University Medical Center. Group 1
consisted of patients newly diagnosed with osteoporosis
and starting treatment with anti-resorptive therapy. In
group 2 patients were included who were already diag-
nosed with osteoporosis and treated with bisphosphonates
for at least three months. Patients were included as part of
a study previously approved by the ethics committee at
the VU University Medical Center.
In both groups height and weight were measured, and
body mass index (BMI) was calculated. DXA measure-
ments (Hologic 4500, Waltham, Mass., USA) of the total
hip and spine (L1-L4) were performed before start of
treatment. Instant Vertebral Assessment (IVA) or a spine
radiograph were performed to detect possible vertebral
fractures. Treatment was started in case of: a T score of ≤
-2.5 in either hip and/or spine, a T score of ≤ -2 and a
clinical fracture, a radiologically confirmed vertebral frac-
ture, or the use of prednisone in a dose of at least 7.5
mg/day during at least three months.
All patients were screened for secondary causes of
osteoporosis through laboratory testing before start of
treatment, including erythrocyte sedimentation rate,
thyroid stimulating hormone, free T4, creatinine, urea,
alkaline phosphatase, calcium and 25(OH) vitamin D.
The first choice of treatment was an oral bisphospho-
nate. In case of (gastro-intestinal) contraindications
patients were given zoledronic acid intravenously once
yearly.
In group 1 P1NP and CTX serum levels were mea-
sured before start of treatment and at their follow up
visit three months later in the same assay. During this
visit patients were asked about compliance and the
occurrence of side effects, in which case another bispho-
sphonate was prescribed.
In group 2 one cross-sectional measurement of serum
P1NP and CTX levels was performed and patients were
asked about compliance during their visit to the outpati-
ent clinic.
Blood samples for both markers were withdrawn in
fasting state, early in the morning. P1NP was measured
by radio immunoassay (Orion Diagnostica, Espoo, Fin-
land) and CTX by electrochemiluminescence (Roche
Diagnostics, Mannheim, Germany).
Patients with a recent fracture (less than 6 months
before the outpatient clinic visit) were excluded.
Reference population
In order to determine the premenopausal range of fast-
ing serum levels of BTMs, P1NP and CTX serum levels
were also measured in a group of 34 healthy premeno-
pausal women born between 1968 and 1989.
Least significant change in P1NP and CTX
The LSC was calculated with the formula: Z × √2 × √
(AV² + IV²), where AV represents the analytical change
in our laboratory, IV the intra-individual variation and Z
is the Z-score. At the 0.95 confidence level, Z is 1.96
[12]. The AV for CTX was 3% and for P1NP 8%. We
used an IV of 10%, based on results found in earlier stu-
dies [9,13]. Using these values for IV and AV the calcu-
lated LSC for CTX was 29% and for P1NP 36%.
Statistics
Changes over time of serum P1NP and CTX levels were
analyzed using a paired samples t test. Differences
between groups were analyzed using an independent t
test. The software used for statistical analyses was SPSS
for Windows, version 15 (SPSS, Chicago, IL).
Results
Because the values were not distributed normally in the
reference population, we calculated the median (range)
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P1NP level (45 (28-110) μg/L) and CTX level (405 (115-
905) ng/L). These ranges are comparable to those found
in earlier studies [14,15].
Baseline characteristics are presented in Table 1. In
group 1 thirty-one patients that subsequently visited the
osteoporosis outpatient clinic were included, over two
thirds of whom were women. Thirteen patients were
diagnosed with osteoporosis based on a T-score of ≤
-2.5 in their spine and/or hip and sixteen were osteope-
nic. Two patients had a normal BMD, however, they
both had a vertebral fracture.
Bisphosphonate treatment consisted of alendronate (70
mg weekly) in 15 patients, 5 risedronate (35 mg weekly), 4
ibandronate (150 mg monthly) and 7 zoledronic acid
(5 mg intravenously once yearly) because of gastrointest-
inal contraindications for oral bisphosphonates.
After a median treatment duration of 4 months, the
levels of P1NP and CTX decreased both significantly
with 50% and 63% respectively (p < 0.001, Table 2).
Eighty-one percent of the patients showed a decrease
greater than the LSC of both markers. Nearly all
patients reached premenopausal CTX and P1NP values
(respectively 94 and 97%, Table 3).
In Table 4 values of CTX and P1NP, type of treatment
and possible explanation in the patients that did not
decrease ≥ LSC are summarized.
At the outpatient clinic visit after three months
patients were asked about their therapy. One patient
indicated not to have taken the medication at all (nr 6
in Table 4), another patient had taken the medication
less frequently than prescribed and/or occasionally dur-
ing a meal (nr 5). There were no differences between
patients that did show a decrease of ≥ LSC and those
that did not, in age, BMI, vitamin D level, BMD and
type of bisphosphonate.
In group 2 ninety-five patients were included, of
whom 31 patients had also been included in group 1. In
this subgroup of 31 patients, the second measurement
of CTX and P1NP was used for analysis. Group 2 con-
sisted mainly of women. Twenty-four had a T-score of
≤ -2.5 in their spine and/or hip, 47 had a T-score in the
osteopenic range, while 19 patients had a normal BMD.
The patients with a normal BMD were either using pre-
dnisone chronically (3) or had one or more vertebral
fractures (16). Of 5 patients no recent DXA measure-
ment (within 6 months of the cross-sectional measure-
ment of CTX and P1NP) was available.
Bisphosphonates used were: 40 alendronate (70 mg
weekly), 24 risedronate (35 mg weekly), 18 zoledronic acid
(5 mg intravenously, once yearly), 6 ibandronate (150 mg
monthly), 6 pamidronate (60 mg intravenously every three
months) and 1 (alendronate 70 mg/cholecalciferol 2800 IU
weekly). Three patients were non-compliant, among
whom nr 5 and 6 described in Table 4. The mean serum
levels of P1NP (22 μg/L) and CTX (137 ng/L) were in the
lower half of the premenopausal range. Of all patients 90
(95%) had a serum P1NP level in the lower half of the pre-
menopausal range. Serum CTX levels were measured in
84 patients, of whom 80 (95%) had a level in the lower half
of the premenopausal range.
Discussion
In our study, performed in a clinical setting, levels of
P1NP and CTX decreased significantly in most patients
during the first months of treatment with bisphospho-
nates. And, importantly, almost all reached the biological
target of therapy; the lower half of the premenopausal
range. Moreover, in 95% of the patients chronically trea-
ted with bisphosphonates bone turnover markers were
within the aimed premenopausal range. Because signifi-
cant positive effects on bone turnover can be observed
even 3 months after starting therapy, an adequate
Table 1 Baseline characteristics
Variables Group 1
n = 31
Group 2
n = 95
Age (years) mean (SD) 66 (9) 67 (11)
Gender (female) n (%) 22 (71) 75 (79)
BMI (kg/m2) mean (SD) 26 (5) 25 (5)
T score spine mean (SD) -2.2 (1.1) -2.2 (1.3)
T score hip mean (SD) -1.6 (0.8) -1.6 (0.9)
Baseline characteristics of group 1 (patients starting treatment n = 31) and
group 2 (patients treated > 3 months n = 95).
BMI = body mass index
Table 2 Changes in BTM levels
Variables Baseline Follow up Decrease %
P1NP (μg/L) mean (range) 47 (15-93) 22 (9-49) 50 *
CTX (ng/L) mean (range) 363 (177-718) 128 (10-446) 63 *
Significant changes in BTM levels in group 1 (n = 31) during treatment with
bisphosphonates.
* p < 0.001
P1NP = procollagen type 1 N-terminal propeptide; CTX = C-terminal
crosslinking telopeptide
Table 3 Distribution of Bone Marker Values Compared to
Premenopausal Reference Range Before and On
Bisphosphonate Therapy (at least 3 months)
P1NP (μg/L) CTX (ng/L)
Baseline Follow
up
Baseline Follow
up
Below reference range (%) 4 71 0 52
Lower half of reference
range (%)
14 26 65 45
Upper half of reference
range (%)
42 3 35 3
Above reference range (%) 0 0 0 0
P1NP = procollagen type 1 N-terminal propeptide; CTX = C-terminal
crosslinking telopeptide
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Table 4 Possible explanations in patients with a decrease ≤ LSC
Patient CTX baseline
(ng/L)
CTX follow up
(ng/L)
P1NP baseline
(μg/L)
P1NP follow up
(μg/L)
Decrease CTX
(%)
Decrease P1NP
(%)
Possible explanation Bisphosphonate
1 365 150 35 34 59 3 * Recent fracture § Alen
2 250 13 15 11 95 27 * Prednisone use Alen
3 209 52 25 20 75 20 * Alcohol abuse Alen
4 429 446 54 30 +4 * 44 Paraproteinemia Iban
5 177 151 85 40 15 * 53 Non-compliance Ris
6 311 365 45 49 +17 * +9 * Non-compliance Alen
Values of CTX and P1NP, type of bisphosphonate and possible explanation in patients that did not decrease ≥ LSC during treatment with a bisphosphonate in the first few months.
* a decrease of CTX or P1NP < LSC
§ during the follow up visit the patient mentioned pain in his foot which turned out to be a recent fracture of a metatarsal bone.
Alen = alendronate 70 mg once weekly, Iban = ibandronate 150 mg once monthly, Ris = risedronate 35 mg once weekly
P1NP = procollagen type 1 N-terminal propeptide; CTX = C-terminal crosslinking telopeptide; LSC = least significant change
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suppression of serum P1NP and CTX serum levels might
be a valuable tool to monitor early treatment effect and
persistence to therapy.
Our present study is the first demonstrating a rapid and
significant decrease of BTMs in the first months of treat-
ment with bisphosphonates and a reduction of BTMs to
premenopausal levels in almost all osteoporotic patients
on chronic bisphosphonate treatment in a daily clinical
practice setting. The results of the present study are sup-
ported by previous studies performed in the setting of
clinical trials. A group of 693 women diagnosed with
osteoporosis and at least one vertebral deformity were
treated with risedronate 5 mg daily. Their urinary CTX
decreased with 60% after 3-6 months of treatment [16]. In
a smaller group of 67 patients treated with monthly iban-
dronate, median serum CTX level was reduced with 70%,
already three days after therapy initiation [17]. In a recent
publication from the HORIZON trial P1NP serum levels
decreased with a median of 56% and b-CTX serum levels
decreased with 51% after three yearly infusions with zole-
dronic acid [18].
The fact that almost all patients in our study showed a
similar decrease is quite remarkable considering the fact
that patients participating in a clinical trial are usually
more compliant. Although our study was not designed to
monitor or influence compliance, patients were aware that
the effect of therapy would be monitored, possibly this
information did have a positive effect on persistence.
The suggestion that therapy compliance might be
improved by communicating the monitoring of BTMs
with the patients treated, is supported by the results of the
IMPACT study. The IMPACT study described earlier was
designed to investigate the effect of such early reinforce-
ment using BTMs in patients treated with risedronate.
Depending on their BTM response (> 30% increase, -30%
to 30% change, > 30% decrease) patients received the mes-
sage that their response was, respectively, poor, stable or
good [11].
According to the criteria of the IMPACT trial, no
patient in our study had a poor response and six patients
in group 1 had a stable response of one, or both markers.
In three patients P1NP levels remained stable while CTX
decreased ≥ LSC. A possible explanation for this discre-
pancy might be the fact that the decrease in bone forma-
tion (represented by P1NP) was lagging behind the
decrease in bone resorption (represented by CTX), a nor-
mal phenomena in the treatment with anti-resorptives.
The suppression of bone formation can occur up to three
months later than the suppression of resorption [8]. In
one patient both markers remained stable, which was
explained by non-compliance.
In the group of patients using chronic bisphospho-
nates, most patients had a CTX and P1NP level below
the premenopausal median. In two patients both
markers were above the median. One of the two was
non-compliant, the other patient was also diagnosed
with rheumatoid arthritis, which can cause elevated
BTMs [19]. In two patients only CTX was above the
median, one of whom was being treated with prednisone
for polymyositis and phenytoin for epilepsy. Of the two
patients with a P1NP level above the median, one was
using a wheelchair (decreased mobility) and the other
was non-compliant.
Our study has several limitations. Although the group
patients with a cross-sectional measurement is quite sub-
stantial, the group of patients starting bisphosphonates is
relatively small. To our knowledge however, no previous
studies concerning the follow up of BTMs in daily clinical
practice have been published before. Secondly, we did not
measure compliance in a standardized manner. In our
study population self-reported compliance rates were
quite high. More objective information from digital dis-
pensers or pharmacies possibly could have revealed lower
rates. Most patients however had a decline of BTMs dur-
ing follow up and/or levels in the desired therapeutic
range when measured cross-sectionally, suggesting that
they were indeed taking their medication as prescribed. In
both groups a number of patients (7 and 18) were treated
with zoledronic acid intravenously, obviously compliance
is not an issue in these patients. Thirdly, over half of the
patients starting treatment with a bisphosphonate already
had BTMs in the premenopausal range. (Table 3) How-
ever, in most of these patients a decrease of > 30% could
be seen, Finally, the measurement of markers of bone
turnover in itself has several restrictions, of which the ana-
lytical and pre-analytical variability are the most impor-
tant. The former depends on the marker and the method.
Factors that influence pre-analytical variability can be
divided into two categories; controllable factors, such as
diet, diurnal variation, physical exercise. And variability
that can not be controlled for, such as age, gender, meno-
pausal status, diseases characterised by changes in bone
turnover, and medications [8]. In order to minimize the
effect of both forms of variability all samples were drawn
in fasting state, and results were compared to the results
of measurements in healthy premenopausal controls,
using the same method. By establishing a cut-off value
(LSC, which takes both intra- and intervariability of the
test into account) above which the change is significant,
the effect of variability is further minimized. Ideally sepa-
rate reference groups for different populations would be
created (e.g. men, or patients with RA).
Conclusion
In conclusion, monitoring anti-resorptive treatment
using BTMs in clinical practice is feasible and might be
an important tool in monitoring early treatment effect
and compliance.
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